BSE
Your Result on : Company News Details
Cipla Ltd Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
500087
ISIN Demat
INE059A01026
Book Value (Rs)
432.1356994
NSE Symbol
CIPLA
Divident Yield %
0.92
Market Cap
(Rs In Cr.)
114,720
P/E (TTM)
40.17
EPS (TTM)
35.35
Face Value
(Rs)
2
Back
Invagen Pharmaceuticals enters licensing agreement with Qilu
04-Sep-26   Hrs IST

Invagen Pharmaceuticals Inc, a wholly owned subsidiary of Cipla announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co. (Qilu), for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States.

As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory. The collaboration reflects both companies' shared commitment to addressing the growing burden of cancer and improving access to advanced biologic therapies.

Risk Factor   |   Terms & Conditions   |   Privacy Policy   |   Disclaimer   |  Sitemap 
Important Links:   SEBI   |   NSE   |   BSE   |   MCX   |   NCDEX   |   NSDL   |   CDSL  |   FMC
BSE Delayed market data sourced at 5 minutes – www.bseindia.com
SMS FINANCIAL SERVICES P. LTD -NSE SEBI No. AP1413004363 | BSE SEBI No. AP01091801121968
Ganesh S Shanbhag – AMFI Registered Mutual Fund Distributor. Registration Number – ARN-0988 – Valid Till 01/JUL/ 2027, Date of initial registration: 02/DEC/2004
2017-18 © SMS Financial Services. All rights reserved. Designed, Developed , Maintained and Content Powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)